# Unitree Robotics Stock Plunges 53% From IPO Peak as Humanoid Sector Faces Valuation Reality Check
A Chinese humanoid robot maker that once commanded a stock market valuation rivaling some of the world’s most established technology companies is now confronting a sharp correction that has wiped tens of billions of dollars off its worth in mere weeks. The story of Unitree Robotics’ dramatic fall from grace has become a case study in how quickly investor enthusiasm can outpace sustainable business fundamentals — even for a company that is already generating real money.
## A Stunning Descent From the Top
Unitree Robotics made headlines in August 2026 when its shares debuted on the Shanghai Stock Exchange’s STAR Market under ticker 688836. The initial offering price was set at 150.80 yuan per share, which implied a post-IPO valuation of roughly 61 billion yuan (approximately $9 billion). On the very first day of trading, the stock rocketed higher, climbing as much as 460% before settling at a closing price of 845 yuan — pushing the company’s market capitalization toward 445 billion yuan, or roughly $66 billion.
Fast forward to recent trading sessions, and the picture looks dramatically different. Shares closed at 513.93 yuan (approximately $72.10), representing a decline of nearly 39% from the first-day close and over 53% from the intraday peak of 1,100 yuan. At the height of its valuation, Unitree had destroyed approximately $35 billion in market capitalization from its highest point.
Despite the steep decline, the stock remains more than three times its original IPO price, meaning early investors have still seen substantial gains. The question now is what happens next — and whether the company’s underlying business can justify the price that remains.
## Revenue Tells a Different Story
What makes Unitree’s situation particularly fascinating is that the company is far from a speculative pre-revenue venture. Unitree generated 1.70 billion yuan (approximately $252 million) in revenue during 2025, a dramatic increase from 392.77 million yuan the year before. The company sells a range of products including bipedal humanoids, quadruped robots, and various robotic components.
Humanoid robots have become a significant revenue driver. In 2025 alone, humanoid-related revenue reached 868 million yuan, accounting for more than half of total sales. The company delivered over 5,500 humanoid units during the year — a meaningful number that signals genuine commercial traction rather than theoretical potential.
Looking ahead, Unitree projected first-half 2026 revenue between 1.052 billion and 1.128 billion yuan, suggesting continued year-over-year growth of 36% to 45%. At these rates, full-year 2026 revenue could easily exceed 2 billion yuan for the first time.
## The Valuation Gap
Even at the reduced stock price, Unitree’s current valuation of roughly $30 billion implies a price-to-revenue ratio of approximately 125x based on 2025 figures. When measured against adjusted earnings, the multiple balloons to more than 350x. At its zenith, the company traded at over 250 times its annual revenue.
To put that into perspective, compare Unitree with Agility Robotics, the Oregon-based humanoid developer that recently disclosed its financials through a proposed SPAC merger with Churchill Capital Corp. XI. Agility reported just $1.78 million in net sales for 2025, accompanied by a $140.2 million operating loss and a $138.1 million net loss. The company poured roughly $91.6 million into research and development while ending the year with about $103 million in cash. Despite these modest numbers, the proposed SPAC values Agility at approximately $2.5 billion — roughly 1,400 times its annual revenue.
The contrast highlights just how differently the market is pricing these two companies, even though both are working to commercialize humanoid robots in industrial environments. Unitree has actual shipped products and documented revenue. Agility has promising pilot deployments — with its Digit robots accumulating over 65,000 operating hours across nine customer sites and more than $300 million in multi-year contracted orders for its next-generation Digit v5 model. Yet neither company has proven that humanoids can generate meaningful, repeatable industrial revenue at scale.
## Regulatory Scrutiny Intensifies
Unitree’s stock slide coincides with a broader tightening of sentiment toward humanoid companies seeking public listings in China. Reports indicate that the China Securities Regulatory Commission has informally signaled to investment banks and prospective issuers that humanoid IPO candidates should demonstrate recurring revenue streams, meaningful progress toward profitability, or substantive technological innovation that sets them apart.
While neither the CSRC nor major Chinese financial regulators have formally commented on the reports, the effect on the market has been clear. The scrutiny raises important questions about what constitutes a genuine humanoid business versus one that is riding hype. Less than 10% of Unitree’s 2025 revenue came from industrial applications, while over 40% originated from overseas markets — meaning the vast majority of domestic revenue comes from non-industrial use cases.
Compounding the picture, China has established more than 90 humanoid training centers nationwide, many of which receive co-funding from local governments and robot manufacturers. These centers purchase humanoid robots and use them primarily to generate training data, often through teleoperation setups. Whether these purchases represent sustainable commercial demand or largely subsidized activity is a central question that investors are now wrestling with.
## The Bigger Picture for Humanoid Robotics
The Unitree correction should not be interpreted as a rejection of humanoid robotics as an industry. The technology is advancing rapidly, and there are real-world deployments happening across manufacturing, logistics, and research environments. The question is whether current valuations — on both sides of the Pacific — reflect realistic expectations or speculative momentum.
Unitree has done something most humanoid developers have not: it has built a revenue base. The challenge now is demonstrating that this revenue is sustainable, repeatable, and capable of scaling further as the market matures. Investors who once valued the company at $66 billion are now recalibrating to something closer to $30 billion, and that recalibration may not be complete.
—
## Frequently Asked Questions (FAQ)
**Q: What caused Unitree’s stock to drop so sharply after its IPO?**
A: The decline reflects a market correction from the extraordinary first-day valuation rather than a loss of confidence in the company’s business fundamentals. After reaching a peak of 1,100 yuan and a valuation near $66 billion, investors appear to be reassessing whether such multiples are justified for a company that is still in its early commercial stage.
**Q: Is Unitree actually profitable?**
A: Unitree is generating significant revenue — $252 million in 2025 — and the article references its adjusted earnings, suggesting profitability on a modified basis. Unlike many humanoid competitors, Unitree is not operating at a loss relative to revenue. However, the high valuation multiples relative to both revenue and earnings suggest investors are pricing in substantial future growth.
**Q: How does Unitree compare to U.S.-based humanoid companies?**
A: Unitree has far more revenue than most U.S. humanoid developers. Agility Robotics, for example, generated just $1.78 million in net sales in 2025 while recording a $138.1 million net loss. Other companies like 1X Technologies, Apptronik, and Figure have not publicly disclosed comparable revenue figures, but they are also at early commercial stages. Boston Dynamics’ humanoid program (Atlas) is a small part of a broader revenue mix dominated by its Spot and Stretch robots.
**Q: What is the China Securities Regulatory Commission doing about humanoid IPOs?**
A: According to media reports, Chinese regulators have informally raised standards for humanoid companies seeking to go public, asking them to demonstrate recurring revenue, progress toward reducing losses, or significant technological innovation. These reports have not been formally confirmed by regulators.
**Q: Is the humanoid robotics sector a bubble?**
A: While valuations across the sector — particularly in China — are exceptionally high relative to current revenue, it would be premature to call the entire sector a bubble. Companies like Unitree are generating real revenue from real products. The key challenge will be whether that revenue can grow fast enough to justify the capital markets have assigned to these businesses.
**Q: How many humanoid robots did Unitree sell in 2025?**
A: Unitree shipped more than 5,500 humanoid units during 2025, representing a substantial commercial deployment at this stage of the technology’s development.
**Q: Where does Unitree sell its robots?**
A: More than 40% of Unitree’s 2025 revenue came from overseas markets, while roughly 60% was domestic. The company sells humanoids, quadrupeds, and various robotic components to customers worldwide.
—
## Conclusion
The sharp decline in Unitree Robotics’ share price serves as a powerful reminder that IPO excitement and market reality can be very different things. Even a company with genuine revenue, product shipments, and commercial customers is not immune to the forces of valuation compression when initial pricing proves aggressive.
At the same time, Unitree’s financial profile is remarkably stronger than most of its peers. The company has achieved what few others in the humanoid space have managed: consistent revenue growth and meaningful unit sales. The challenge going forward is not proving that Unitree can build a business — it already has — but rather proving that the business can grow at a pace that justifies the capital markets’ attention.
For investors, the Unitree story underscores the importance of separating genuine commercial progress from speculative narrative. For the broader humanoid robotics industry, it highlights the growing need for transparency, sustainable business models, and realistic expectations about timelines. The era of valuing humanoid companies primarily on potential rather than performance may be giving way to a more disciplined approach — and that shift, while painful in the short term, could ultimately benefit the long-term health of the sector.
Thank you for reading
